Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

Is Abraxane® (nanoparticle albumin-bound [NAB] paclitaxel) as good as Taxotere® (docetaxel)?

0
Posted

Is Abraxane® (nanoparticle albumin-bound [NAB] paclitaxel) as good as Taxotere® (docetaxel)?

0

NAB paclitaxel has been compared to docetaxel in a recent randomized phase II trial. The weekly schedule of NAB paclitaxel has been shown to be more efficacious compared with every 3 weeks for docetaxel. A pivotal phase 3 trial comparing NAB paclitaxel weekly to every 3 weeks for docetaxel is planned. However, both agents have been compared with Taxol® (paclitaxel) in separate randomized studies. In the trial where NAB paclitaxel was compared with paclitaxel, NAB paclitaxel could be given in a higher dose (260 mg versus 175 mg/m2), which resulted in more shrinkage of tumors and longer time to progression. Although toxicity to nerves was observed more frequently with NAB paclitaxel, it was shorter lived. This was believed to be due to the lack of the toxic solvent Cremophor (castor oil), which is used with paclitaxel to make it soluble. A separate trial comparing docetaxel with paclitaxel showed docetaxel was better for shrinking tumors, time to progression, and overall survival at the

0

NAB paclitaxel has been compared to docetaxel in a recent randomized phase II trial. The weekly schedule of NAB paclitaxel has been shown to be more efficacious compared with every 3 weeks for docetaxel. A pivotal phase 3 trial comparing NAB paclitaxel weekly to every 3 weeks for docetaxel is planned. However, both agents have been compared with Taxol® (paclitaxel) in separate randomized studies. In the trial where NAB paclitaxel was compared with paclitaxel, NAB paclitaxel could be given in a higher dose (260 mg versus 175 mg/m2), which resulted in more shrinkage of tumors and longer time to progression. Although toxicity to nerves was observed more frequently with NAB paclitaxel, it was shorter lived. This was believed to be due to the lack of the toxic solvent Cremophor (castor oil), which is used with paclitaxel to make it soluble. These studies have been completed in patients with metastatic disease. A separate trial comparing docetaxel with paclitaxel showed docetaxel was better

Related Questions

What is your question?

*Sadly, we had to bring back ads too. Hopefully more targeted.

Experts123